LISA BEYERS: Open Payments
NPI 1104538685 · OAKTOWN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$416 in 20 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $70 · 2025 $416
Food & beverage: $416
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $107 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| ABBVIE INC. | 2 | $48 |
| PFIZER INC. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Novo Nordisk Inc | 2 | $30 |
| Seqirus USA Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $17 |
| Amgen Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: CAPLYTA, REXULTI, QULIPTA, PREVNAR 20, AUSTEDO XR, Ozempic, Fluad, ZEPBOUND.
Industry payments across IN — which companies pay providers there.
